Pharmacy evidence record · researched 2026-08-20

Medivant Healthcare

Tailstorm Health Inc. dba Medivant Health

3 citations8 action records6 explicit unknowns

Compounded with

Semaglutide

Not verified in the bound record.

Tirzepatide

Not verified in the bound record.

Product evidence does not establish current availability.

Locations in the source record

  • 24416 N 19th Ave, Suite 200, Phoenix, AZ 85085
  • 158 S Kyrene Rd, Chandler, AZ

Services named by sources

  • 503B sterile injectable manufacturing
  • Outsourcing-facility services
  • Hospital and practitioner sterile-product supply

Regulatory compliance

503 pathway evidence

A pathway label describes which federal rules apply — it is not a quality claim.

Section 503A

Source-backed negative

not supported

Section 503B

Source-backed pathway evidence

FDA's action index labels both facilities 503B. Exact rows from the current weekly registry were not recovered.

Telehealth providers

No provider relationship is verified in the bound sources.

Clinic Scout links a provider only when an explicit source names the relationship.

Browse provider records

Regulatory history

Actions stay dated and bounded.

FDA warning/closeout, untitled-letter, FMD-145, Form 483/current-503B and Arizona board sources were checked. No Arizona state-board action was verified.

U.S. Food and Drug Administration · 2021-07-21

Form FDA 483

Status not stated

U.S. Food and Drug Administration · 2022-06-17

Untitled Letter

Status not stated

U.S. Food and Drug Administration · 2023-10-23

FMD-145 letter

Status not stated

U.S. Food and Drug Administration · 2024-10-10

Form FDA 483

Status not stated

U.S. Food and Drug Administration · 2025-04-08

Warning Letter

FDA stated that products failed to meet section 503B conditions and that investigators observed serious production-practice deficiencies.

closed_out_2026-03-23

U.S. Food and Drug Administration · 2025-05-23

Form FDA 483

Status not stated

U.S. Food and Drug Administration · 2025-11-14

Form FDA 483

Status not stated

U.S. Food and Drug Administration · 2026-03

FMD-145 letters / warning closeout

FDA's action index lists FMD-145 letters on March 19 and 20 and warning-letter closeout on March 23, 2026.

Status not stated

What remains unverified

No Clinic Scout patient reviews are published for this pharmacy. Submissions go through manual moderation before anything appears here.

What this record verifies for you

6 evidence dimensions carry dated, source-backed verification.

Each line traces to a citation in the source list below — read the exact captured wording before relying on it.

No superiority claim is made for review volume, ratings, or patient sentiment.

Sources and exact captured wording

  1. first_party · accessed 2026-08-20
    Medivant Healthcare is a U.S.-based 503B outsourcing facility specializing in sterile injectable medications.
  2. fda · accessed 2026-08-20
    You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B ... From September 24, 2024, to October 10, 2024, an FDA investigator inspected your facility, Tailstorm Health Inc. dba Medivant Health
  3. fda · accessed 2026-08-20
    Tailstorm Health, Inc., Chandler, AZ - 503B Facility ... Tailstorm Health, Inc., Phoenix, AZ - 503B Facility ... Warning Letter Close Out Issued 03/23/2026 ... Warning Letter Issued 04/08/2025

Questions readers ask

Is Medivant Healthcare legit?

GLP Clinic Scout does not issue a blanket legitimacy verdict. This research record preserves 3 dated first-party or regulator citation(s), 8 regulatory/action record(s), and 6 explicitly unresolved field(s). Review the cited evidence and current license status before making a decision.

Still have questions? Read the research library or email us at [email protected].